Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety

Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. 

Badrinath Konety, MD, MBA, is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the Institute for Prostate and Urologic Cancers. He is also Associate Director, Clinical Affairs & Clinical Research, Masonic Cancer Center (MCC)

Alicia Morgans, MD, MPH

Read More:

Bladder Cancer BioMarkers: Optimal Utilization for Diagnosis and Recurrence

Watch: Bladder Cancer Biomarkers: Optimal utilization for diagnosis and recurrence pipeline- Badrinath Konety

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.